Role of Extended Low Dose Prednisolone in Achieving Clinical and Biochemical Remission in Steroid Responsive Severe Alcoholic Hepatitis

NCT ID: NCT06155760

Last Updated: 2023-12-04

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-11-25
• Study Completion Date: 2025-02-27

Brief Summary

Severity of alcoholic hepatitis is defined by Maddrey's discriminant function, value of 32 or higher indicates severe alcoholic hepatitis that carries an adverse prognosis with one month mortality of 30%-50%. Prednisolone (40 mg/day) given orally should be considered to improve 28-day mortality in patients with severe AH. Abstinence is key to long-term survival.

According to current protocol, we discontinue the treatment after 28 days but only 15 % patient is achieving the DF < 32 after 28 days of treatment.

The aim of this study is to evaluate the role of extended low dose prednisolone (10mg) in achieving remission by day-90 in steroid responsive severe alcoholic hepatitis.

Detailed Description

Study Design- Single center, Open label, Randomized controlled trial

• According to current protocol, we discontinue the treatment after 28 days, it improve the mortality rate in severe alcoholic patient with mDF score of more than 32 but only 15% patient is achieving the mDF < 32 after 28 days of treatment.
• Abstinence is key to long-term survival. No data is available in giving steroids for more than 28days going to improve clinical or biochemical parameter of the patient.

Methodology:

• Study population: All patients aged ≥ 18 years and ≤ 60 years admitted in Institute of Liver and Biliary Sciences, New Delhi with Severe Alcoholic hepatitis mDF of more than 32 days after 28days of steroid therapy and are giving written consent for participation in the study. Option of LDLT, Plasma exchange, FMT, GM- CSF given to patient with DF more than 32 after 28 days of steroid therapy and these patients are excluded from the study.
• Study period - 1.5 years after IEC approval
• Sample size - We are enrolling 150 patients.- Assuming that the response rate is 50% in prednisolone + SMT group and 20% in only SMT group. With alpha- 5% and power of 80, we need to enroll - 90 cases i.e, 45 in each group. Further adding 10% drop out cases, it was decided to enroll 100 patients i.e, 50 in each group. Allocation will be done randomly by block randomization panel by block size of 10. Further assuming that DF > 32 will be in 80% cases we need to enroll 125 cases. Further 80% will have lille score < 0.45, so it is to decide to enroll 150 cases.
• Intervention - Extended steroid group: 10mg of prednisolone plus standard medical therapy for 60 days.
• Placebo group: Standard treatment plus placebo that the patient would receive included in the trial.
• SMT- IV Albumin, Diuretics, Multi vitamins as per clinicians decision
• Monitoring and assessment:
• Investigations - Tests performed on Day 0, 4, 7, 28, 60 and 90.

• Routine: CBC, RFT, LFT, PT/INR, CXR, PCT, Urine R/M & C/S, Blood C/S,
• Blood sugar- fasting & PP.
• Statistical Analysis: The data will be represented as mean ± SD. The categorical data will be analysed using Chi-square test. The continuous data will be analysed by student T test, or Mann-Whitney test, whichever is applicable. Besides this, Cox regression will be applied to analyse the variables. For all tests, p≤ 0.05 will be considered statistically significant
• Adverse effects
• New onset Diabetes, risk of infection
• Stopping rule
• Discontinuation of steroids (variceal bleed, infections, uncontrolled sugars, new onset AKI)
• Death
• Liver transplantation
• Lapse or relapse of alcohol consumption

Expected outcome of the project:

• Improvement in the mDF score (<32) i.e. Remission in severe alcoholic hepatitis.

Conditions

Severe Alcoholic Hepatitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Extended Steroid Therapy

10mg of prednisolone plus standard medical therapy for 60 days. SMT- IV Albumin, Diuretics, Multi vitamins as per clinicians decision

Group Type: EXPERIMENTAL

Prednisolone

Intervention Type: DRUG

10mg of prednisolone plus standard medical therapy for 60 days

Standard Medical therapy

Intervention Type: OTHER

IV Albumin, Diuretics, Multi vitamins as per clinicians decision

Placebo group

Standard treatment plus placebo that the patient would receive included in the trial.

SMT- IV Albumin, Diuretics, Multi vitamins as per clinicians decision

Group Type: ACTIVE_COMPARATOR

Standard Medical therapy

Intervention Type: OTHER

IV Albumin, Diuretics, Multi vitamins as per clinicians decision

Placebo

Intervention Type: DRUG

Placebo

Interventions

Prednisolone

10mg of prednisolone plus standard medical therapy for 60 days

Intervention Type: DRUG

Standard Medical therapy

IV Albumin, Diuretics, Multi vitamins as per clinicians decision

Intervention Type: OTHER

Placebo

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Persistence of mDF > 32 at day 28 of steroids.

Exclusion Criteria

1. Active infection

2. Uncontrolled sugars

3. No consent

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Institute of Liver and Biliary Sciences, India

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Institute of Liver & Biliary Sciences (ILBS)

New Delhi, National Capital Territory of Delhi, India

Countries

India

Central Contacts

Dr Ravi Nishad, MD

Role: CONTACT

Phone: 01146300000

Email: ravinishad.422@gmail.com

Facility Contacts

Dr Ravi Nishad, MD

Role: primary

Other Identifiers

ILBS-ALD-03

Identifier Type: -

Identifier Source: org_study_id